11β-HSD1 Inhibitor Alleviates Non-Alcoholic Fatty Liver Disease by Activating the AMPK/SIRT1 Signaling Pathway. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.